CytoMed Therapeutics Chairman to Acquire 112,000 Shares via Private Transaction

On May 13, 2026, CytoMed Therapeutics Limited reported that its Chairman and Director, Mr. Choo Chee Kong, entered into a binding private share purchase agreement to acquire 112,000 ordinary shares of the company. The transaction was conducted with an independent arm-length shareholder for cash consideration via a privately negotiated transaction. CytoMed Therapeutics was not a party to this transaction and did not receive any proceeds from the sale. Furthermore, Mr. Choo indicated his intention to engage in additional private negotiations with other independent shareholders to further increase his equity stake in the company. This move reflects insider buying activity by the company's leadership. The filing was submitted to the SEC on Form 6-K on May 15, 2026.